Mr. Peikwen Cheng is Co-founder and CEO of Yiviva, a biotechnology company that develops first-in-class therapeutics. Yiviva developed YIV906, an herbal mixture based on 1,800-year-old Chinese formula.
A number of clinical studies show YIV906 reduces the harmful adverse side effects of chemotherapy and increases the efficacy of cancer therapies.
The results of these studies, together with years of research at the Yale School of Medicine, helped the company win the Innovation Award at the U.S.-China Health Summit in 2016.
Mr. Cheng previously co-founded WideRay/Qwikker, which distributed media, content and applications to mobile devices. For instance, his team created technology that helped rural healthcare workers in Uganda improve patient management and communicate with the central hospital instantly, versus a six-month lag.
Mr. Cheng holds a U.S. patent, and he received the 2002 Industrial Design Excellence Award by IDSA and BusinessWeek.
Based on the research of Yale Pharmacology Professor Yung-Chi Cheng, Yiviva develops botanical medicine-inspired therapeutics to treat chronic diseases and cancer. Yung-Chi Cheng also serves as co-specialty chief editor of the specialty section Ethnopharmacology in Frontiers in Pharmacology.
The National Foundation for Cancer Research has provided critical support for research coming out of Prof. Cheng’s lab from early research in 1991 into clinical trials.
“We’ve had almost 200 patients use our cancer drug (906) in liver, pancreatic and colorectal cancer, and consequently, we’re seeing patients live longer with better quality of life and recover faster,” Prof. Cheng says.
He adds that crucial funding from NFCR has enabled an idea to see real patient outcomes.
“The mission of NFCR is not just to help with early stage funding of research, but now they’re helping us out with mid-stage to later stage,” Prof. Cheng says. “We believe this funding will really help catalyze the future development of these ideas – especially the more breakthrough, out-of-the-box ideas such as ours, which sometimes need the help of a more visionary investor for support.”